Bellerophon Therapeutics - BLPH Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLPH shares.
View BLPH analyst ratings or view top-rated stocks.

1 analysts have issued 1 year target prices for Bellerophon Therapeutics' shares. Their BLPH share price forecasts range from $19.00 to $19.00. On average, they predict the company's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 1,238.0% from the stock's current price.
View analysts price targets for BLPH or view top-rated stocks among Wall Street analysts.

Bellerophon Therapeutics' stock was trading at $3.10 at the beginning of 2022. Since then, BLPH shares have decreased by 54.2% and is now trading at $1.42.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 18th 2022.
View our BLPH earnings forecast.

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) announced its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.14.

Shares of Bellerophon Therapeutics reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

(BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Bellerophon Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.19%) and Sepio Capital LP (0.25%). Insiders that own company stock include Associates Iv L P Venrock, New Mountain Investments Ii, L, Theodore T Wang and Wassim Fares.
View institutional ownership trends.

Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLPH stock can currently be purchased for approximately $1.42.

Bellerophon Therapeutics (NASDAQ:BLPH) has a market capitalization of $13.55 million. The biotechnology company earns $-17,760,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The official website for the company is www.bellerophon.com. The biotechnology company can be reached via phone at (908) 574-4770 or via email at btinvestorrelations@bellerophon.com.